medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2006, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2006; 51 (2)

Efficacy of a macrolid-azalid on the simptomatology and bacterial count in patients with acute bacterial conjunctivitis. Pilot study

Villalba-Ortiz P, Vanzzini V

Language: Spanish
References: 13
Page: 70-73
PDF size: 83.28 Kb.


ABSTRACT

Acute bacterial conjunctivitis is extremely frequent but autolimited, thus indiscriminate use of local antibiotics produces resistance, making it a challenge to produce new compounds that are easy to obtain, easy to manage and with excellent efficacy to treat this disease. Objective: Evaluate the clinical activity of a stable azalid of erythromycin. Method and materials: Twelve patients with acute bacterial conjunctivitis were studied in whom bacterial colonies were counted and analogical scales of symptoms and signs were recorded during 3 consecutive days. The kinetics of the reduction of the bacterial colonies was evaluated after the instalation of the azalid to correlate with the clinical response. Results: Every patient referred symptomatological satisfaction, clinical scales got significantly better and the bacterial counts were reduced substantially at the end of the 3 day treatment period. Nineteen patients had a positive culture for Staphylococcus epidermidis. All the patients withheld the treatment. Conclusions: The use of this azalid is effective for the treatment of acute bacterial conjunctivitis due to its high efficacy in the eradication of the most frequent pathogens causing this disease.


REFERENCES

  1. Kanski JJ. Oftalmología clínica. 3a ed. Barcelona: Doyma Libros, 1996; 55-61.

  2. Spalton DJ, Hitching RA, Hunter PA. Atlas de oftalmología clínica. 2a ed. Madrid: Mosby/Doyma Libros, 1995; 3.2-4.22.

  3. Graue WE. Oftalmología: En la práctica de la medicina general. México: Iberoamericana-McGraw-Hill, 1995; 75-92.

  4. Jawetz E et al. Microbiología médica. 14a ed. México: Manual Moderno, 1992; 35-42, 141-192.

  5. Hardman JG, Goodman GA, Limbird LE. Goodman & Gillman's the pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill, 1994; 1018-1145.

  6. Cagle G, Abshire R. Quantitative ocular bacteriology: A method for the enumeration and identification of bacteria from the skin-lash margin and conjunctiva. Invest Ophthalmol Vis Sci 1981; 20: 751-757.

  7. Mandel GL, Douglas R, Douglas G, Bennett JE. Manual de enfermedades infecciosas. Principios y práctica. 7a ed. México: Panamericana, 1992; 370-379.

  8. Chern KC et al. Alterations in the conjuntival bacterial flora following a single dose of azithromycin in trachoma endemic areas. Br J Ophthalmol 1999; 83: 1332-1335.

  9. Bowman RJ, Sillah A, van Deahn C, Goode VM et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci 2000; 41: 4074-4079.

  10. Murray PR, Baron EJ, Pfaller MA, Tenover FC. Manual of clinical microbiology. 6th ed. Washington: ASM Press, 2005; 1342-1433.

  11. Pechere JC. Neap respective on macrolid antibiotics. Int J Antimicrob Agents 2001; 18 (suppl 1): 93-97.

  12. Treadway G. Azithromycin: A new 15-membered macrolide. Jpn J Antibiot 2001; 54 (suppl A): 70-76.

  13. Glasser DB, Baum J. Antibacterial agents. In: Infections of the eye. 1996:207-230.




2020     |     www.medigraphic.com